Modes of Action of TLR7 Agonists in Cancer Therapy

References

• Gay NJ, Keith FJ. Drosophila Toll and IL-1 receptor. Nature 351(6325),355–356(1991).
   PubMed Web of Science ®Google Scholar
• Roach JC, Glusman G, Rowen L et al. The evolution of vertebrate Toll-like receptors. Proc. Natl. Acad. Sci. USA 102(27), 9577–9582(2005).
   PubMed Web of Science ®Google Scholar
• Uematsu S, Akira S. Toll-like receptors and innate immunity. J. Mol. Med. (Berl.) 84(9), 712–725(2006).
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Eggermont A, Sautes-Fridman C et al. Trial watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology 2(8), e25238(2013).
   PubMed Web of Science ®Google Scholar
• Wiemann B, Starnes CO. Coley’s toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol. Ther. 64(3), 529–564(1994).
   PubMed Web of Science ®Google Scholar
• Engelhardt R, Mackensen A, Galanos C. Phase I trial of intravenously administered endotoxin (Salmonella abortus equi) in cancer patients. Cancer Res. 51(10), 2524–2530(1991).
   PubMed Web of Science ®Google Scholar
• Witt PL, Ritch PS, Reding D et al. Phase I trial of an oral immunomodulator and interferon inducer in cancer patients. Cancer Res. 53(21), 5176–5180(1993).
   PubMed Web of Science ®Google Scholar
• Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5(6), 471–484(2006).
   PubMed Web of Science ®Google Scholar
• Dudek AZ, Yunis C, Harrison LI et al. First in human Phase I trial of 852A, a novel systemic Toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. Clin. Cancer Res. 13(23), 7119–7125(2007).
   PubMed Web of Science ®Google Scholar
• Holldack J. Toll-like receptors as therapeutic targets for cancer. Drug Discov Today 19(4), 379–382(2013).
   PubMed Web of Science ®Google Scholar
• Bourquin C, Hotz C, Noerenberg D et al. Systemic cancer therapy with a small molecule agonist of Toll-like receptor 7 can be improved by circumventing TLR tolerance. Cancer Res. 71(15), 5123–5133(2011).
   PubMed Web of Science ®Google Scholar
• Chitwood K, Etzkorn J, Cohen G. Topical and intralesional treatment of nonmelanoma skin cancer: efficacy and cost comparisons. Dermatol. Surg. 39(9), 1306–1316(2013).
   PubMed Web of Science ®Google Scholar
• Arits AH, Mosterd K, Essers BA et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol. 14(7), 647–654(2013).
   PubMed Web of Science ®Google Scholar
• Du X, Poltorak A, Wei Y, Beutler B. Three novel mammalian Toll-like receptors: gene structure, expression, and evolution. Eur. Cytokine Netw. 11(3), 362–371(2000).
   PubMed Web of Science ®Google Scholar
• Adams S, Kozhaya L, Martiniuk F et al. Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Clin. Cancer Res. 18(24), 6748–6757(2012).
   PubMed Web of Science ®Google Scholar
• Geller MA, Cooley S, Argenta PA et al. Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers. Cancer Immunol. Immunother. 59(12), 1877–1884(2010).
   PubMed Web of Science ®Google Scholar
• Walter S, Weinschenk T, Stenzl A et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat. Med. 18(8), 1254–1261(2012).
   PubMed Web of Science ®Google Scholar
• Hornung V, Guenthner-Biller M, Bourquin C et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11(3), 263–270(2005).
   PubMed Web of Science ®Google Scholar
• Kawasaki T, Kawai T, Akira S. Recognition of nucleic acids by pattern-recognition receptors and its relevance in autoimmunity. Immunol. Rev. 243(1), 61–73(2011).
   PubMedGoogle Scholar
• Guiducci C, Coffman RL, Barrat FJ. Signalling pathways leading to IFN-alpha production in human plasmacytoid dendritic cell and the possible use of agonists or antagonists of TLR7 and TLR9 in clinical indications. J. Int. Med. 265(1), 43–57(2009).
   PubMed Web of Science ®Google Scholar
• Engel AL, Holt GE, Lu H. The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system. Exp. Rev. Clin. Pharm. 4(2), 275–289(2011).
   PubMedGoogle Scholar
• Hemmi H, Kaisho T, Takeuchi O et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3(2), 196–200(2002).
   PubMed Web of Science ®Google Scholar
• Applequist SE, Wallin RP, Ljunggren HG. Variable expression of Toll-like receptor in murine innate and adaptive immune cell lines. Int. Immunol. 14(9), 1065–1074(2002).
   PubMed Web of Science ®Google Scholar
• Hornung V, Rothenfusser S, Britsch S et al. Quantitative expression of Toll-like receptor 1–10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 168(9), 4531–4537(2002).
   PubMed Web of Science ®Google Scholar
• Edwards AD, Diebold SS, Slack EM et al. Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8 alpha+ DC correlates with unresponsiveness to imidazoquinolines. Eur. J. Immunol. 33(4), 827–833(2003).
   PubMed Web of Science ®Google Scholar
• Poovassery JS, Bishop GA. Type I IFN receptor and the B cell antigen receptor regulate TLR7 responses via distinct molecular mechanisms. J. Immunol. 189(4), 1757–1764(2012).
   PubMed Web of Science ®Google Scholar
• Clingan JM, Matloubian M. B Cell-intrinsic TLR7 signaling is required for optimal B cell responses during chronic viral infection. J. Immunol. 191(2), 810–818(2013).
   PubMed Web of Science ®Google Scholar
• Bekeredjian-Ding IB, Wagner M, Hornung V et al. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J. Immunol. 174(7), 4043–4050(2005).
   PubMed Web of Science ®Google Scholar
• Alexopoulou L, Desnues B, Demaria O. [Toll-like receptor 8: the awkward TLR]. Med. Sci. (Paris) 28(1), 96–102(2012).
   PubMed Web of Science ®Google Scholar
• Cervantes JL, Weinerman B, Basole C, Salazar JC. TLR8: the forgotten relative revindicated. Cell. Mol. Immunol. 9(6), 434–438(2012).
   PubMed Web of Science ®Google Scholar
• Crozat K, Vivier E, Dalod M. Crosstalk between components of the innate immune system: promoting anti-microbial defenses and avoiding immunopathologies. Immunol. Rev. 227(1), 129–149(2009).
   PubMedGoogle Scholar
• Janke M, Poth J, Wimmenauer V et al. Selective and direct activation of human neutrophils but not eosinophils by Toll-like receptor 8. J. Allerg. Clin. Immunol. 123(5), 1026–1033(2009).
   PubMed Web of Science ®Google Scholar
• Ablasser A, Poeck H, Anz D et al. Selection of molecular structure and delivery of RNA oligonucleotides to activate TLR7 versus TLR8 and to induce high amounts of IL-12p70 in primary human monocytes. J. Immunol. 182(11), 6824–6833(2009).
   PubMed Web of Science ®Google Scholar
• Smits EL, Ponsaerts P, Berneman ZN, Van Tendeloo VF. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 13(8), 859–875(2008).
   PubMed Web of Science ®Google Scholar
• Liu J, Xu C, Hsu LC, Luo Y, Xiang R, Chuang TH. A five-amino-acid motif in the undefined region of the TLR8 ectodomain is required for species-specific ligand recognition. Mol. Immunol. 47(5), 1083–1090(2010).
   PubMed Web of Science ®Google Scholar
• Gorden KK, Qiu X, Battiste JJ, Wightman PP, Vasilakos JP, Alkan SS. Oligodeoxynucleotides differentially modulate activation of TLR7 and TLR8 by imidazoquinolines. J. Immunol. 177(11), 8164–8170(2006).
   PubMed Web of Science ®Google Scholar
• Meier A, Chang JJ, Chan ES et al. Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat. Med. 15(8), 955–959(2009).
   PubMed Web of Science ®Google Scholar
• Torcia MG, Nencioni L, Clemente AM et al. Sex differences in the response to viral infections: TLR8 and TLR9 ligand stimulation induce higher IL10 production in males. PLoS ONE 7(6), e39853(2012).
   PubMed Web of Science ®Google Scholar
• Berghofer B, Frommer T, Haley G, Fink L, Bein G, Hackstein H. TLR7 ligands induce higher IFN-alpha production in females. J. Immunol. 177(4), 2088–2096(2006).
   PubMed Web of Science ®Google Scholar
• Seillet C, Laffont S, Tremollieres F et al. The TLR-mediated response of plasmacytoid dendritic cells is positively regulated by estradiol in vivo through cell-intrinsic estrogen receptor alpha signaling. Blood 119(2), 454–464(2012).
   PubMed Web of Science ®Google Scholar
• Han JH, Park SY, Kim JB et al. TLR7 expression is decreased during tumour progression in transgenic adenocarcinoma of mouse prostate mice and its activation inhibits growth of prostate cancer cells. Am. J. Reprod. Immunol. 70(4), 317–326(2013).
   PubMed Web of Science ®Google Scholar
• Kang S-J, Tak J-H, Cho J-H, Lee H-J, Jung Y-J. Stimulation of the endosomal TLR pathway enhances autophagy-induced cell death in radiotherapy of breast cancer. Genes Genomics 32(6), 599–606(2010).
   Web of Science ®Google Scholar
• Cherfils-Vicini J, Platonova S, Gillard M et al. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J. Clin. Invest. 120(4), 1285–1297(2010).
   PubMed Web of Science ®Google Scholar
• Ochi A, Graffeo CS, Zambirinis CP et al. Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans. J. Clin. Invest. 122(11), 4118–4129(2012).
   PubMed Web of Science ®Google Scholar
• Smith EB, Schwartz M, Kawamoto H et al. Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder. J. Urol. 177(6), 2347–2351(2007).
   PubMed Web of Science ®Google Scholar
• Spaner DE, Miller RL, Mena J, Grossman L, Sorrenti V, Shi Y. Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod. Leuk. Lymphom. 46(6), 935–939(2005).
   PubMed Web of Science ®Google Scholar
• Smits EL, Cools N, Lion E et al. The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells. Cancer Immunol. Immunother. 59(1), 35–46(2010).
   PubMed Web of Science ®Google Scholar
• Bao M, Liu YJ. Regulation of TLR7/9 signaling in plasmacytoid dendritic cells. Protein Cell 4(1), 40–52(2013).
   PubMed Web of Science ®Google Scholar
• Yang Y, Liu B, Dai J et al. Heat shock protein gp96 is a master chaperone for Toll-like receptors and is important in the innate function of macrophages. Immunity 26(2), 215–226(2007).
   PubMed Web of Science ®Google Scholar
• Kim YM, Brinkmann MM, Paquet ME, Ploegh HL. UNC93B1 delivers nucleotide-sensing Toll-like receptors to endolysosomes. Nature 452(7184), 234–238(2008).
   PubMed Web of Science ®Google Scholar
• Ewald SE, Engel A, Lee J, Wang M, Bogyo M, Barton GM. Nucleic acid recognition by Toll-like receptors is coupled to stepwise processing by cathepsins and asparagine endopeptidase. J. Exp. Med. 208(4), 643–651(2011).
   PubMed Web of Science ®Google Scholar
• Li L, Cousart S, Hu J, McCall CE. Characterization of interleukin-1 receptor-associated kinase in normal and endotoxin-tolerant cells. J. Biol. Chem. 275(30), 23340–23345(2000).
   PubMed Web of Science ®Google Scholar
• Lin SC, Lo YC, Wu H. Helical assembly in the MyD88–IRAK4–IRAK2 complex in TLR/IL-1R signalling. Nature 465(7300), 885–890(2010).
   PubMed Web of Science ®Google Scholar
• Kawai T, Sato S, Ishii KJ et al. Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat. Immunol. 5(10), 1061–1068(2004).
   PubMed Web of Science ®Google Scholar
• Ninomiya-Tsuji J, Kishimoto K, Hiyama A, Inoue J, Cao Z, Matsumoto K. The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 398(6724), 252–256(1999).
   PubMed Web of Science ®Google Scholar
• Sun L, Deng L, Ea CK, Xia ZP, Chen ZJ. The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol. Cell. 14(3), 289–301(2004).
   PubMed Web of Science ®Google Scholar
• Zhang G, Ghosh S. Toll-like receptor-mediated NF-kappaB activation: a phylogenetically conserved paradigm in innate immunity. J. Clin. Invest. 107(1), 13–19(2001).
   PubMed Web of Science ®Google Scholar
• Gorden KB, Gorski KS, Gibson SJ et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J. Immunol. 174(3), 1259–1268(2005).
   PubMed Web of Science ®Google Scholar
• Drobits B, Holcmann M, Amberg N et al. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J. Clin. Invest. 122(2), 575–585(2012).
   PubMed Web of Science ®Google Scholar
• Urosevic M, Oberholzer PA, Maier T et al. Imiquimod treatment induces expression of opioid growth factor receptor: a novel tumor antigen induced by interferon-alpha? Clin. Cancer Res. 10(15), 4959–4970(2004).
   PubMed Web of Science ®Google Scholar
• Tel J, Sittig SP, Blom RA et al. Targeting uptake receptors on human plasmacytoid dendritic cells triggers antigen cross-presentation and robust type I IFN secretion. J. Immunol. 191(10), 5005–5012(2013).
   PubMed Web of Science ®Google Scholar
• Wenzel J, Uerlich M, Haller O, Bieber T, Tueting T. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod. J. Cut. Pathol. 32(4), 257–262(2005).
   PubMed Web of Science ®Google Scholar
• Koga-Yamakawa E, Dovedi SJ, Murata M et al. Intratracheal and oral administration of SM-276001: a selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer. Int. J. Cancer 132(3), 580–590(2013).
   PubMed Web of Science ®Google Scholar
• Rajagopal D, Paturel C, Morel Y, Uematsu S, Akira S, Diebold SS. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists. Blood 115(10), 1949–1957(2010).
   PubMed Web of Science ®Google Scholar
• Inglefield JR, Dumitru CD, Alkan SS et al. TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN. J. Interferon Cytokine Res. 28(4), 253–263(2008).
   PubMed Web of Science ®Google Scholar
• Le Mercier I, Poujol D, Sanlaville A et al. Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment. Cancer Res. 73(15), 4629–4640(2013).
   PubMed Web of Science ®Google Scholar
• Pantel A, Teixeira A, Haddad E, Wood EG, Steinman RM, Longhi MP. Direct type I IFN but not MDA5/TLR3 activation of dendritic cells is required for maturation and metabolic shift to glycolysis after poly IC stimulation. PLoS Biol. 12(1), e1001759(2014).
   PubMed Web of Science ®Google Scholar
• Ito T, Amakawa R, Kaisho T et al. Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J. Exp. Med. 195(11), 1507–1512(2002).
   PubMed Web of Science ®Google Scholar
• Tel J, Schreibelt G, Sittig SP et al. Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets. Blood 121(3), 459–467(2013).
   PubMed Web of Science ®Google Scholar
• Beck B, Dorfel D, Lichtenegger FS et al. Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission. J. Transl. Med. 9, 151(2011).
   PubMed Web of Science ®Google Scholar
• Nair S, McLaughlin C, Weizer A et al. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J. Immunol. 171(11), 6275–6282(2003).
   PubMed Web of Science ®Google Scholar
• Prins RM, Craft N, Bruhn KW et al. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J. Immunol. 176(1), 157–164(2006).
   PubMed Web of Science ®Google Scholar
• Hong X, Dong T, Hu J et al. Synergistical toll-like receptors activated dendritic cells induce antitumor effects against carcinoembryonic antigen-expressing colon cancer. Int. J. Col. Dis. 28(1), 25–33(2013).
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Sznol M, Zhao B et al. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci. Transl. Med. 6(232), 232ra251(2014).
   Web of Science ®Google Scholar
• Fehres CM, Bruijns SC, Van Beelen AJ et al. Topical rather than intradermal application of the TLR7 ligand imiquimod leads to human dermal dendritic cell maturation and CD8 T-cell cross-priming. Eur. J. Immunol. 44(8), 2145–2124(2014).
   Web of Science ®Google Scholar
• Stary G, Bangert C, Tauber M, Strohal R, Kopp T, Stingl G. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J. Exp. Med. 204(6), 1441–1451(2007).
   PubMed Web of Science ®Google Scholar
• Kalb ML, Glaser A, Stary G, Koszik F, Stingl G. TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-alpha-mediated antitumor reactivity. J. Immunol. 188(4), 1583–1591(2012).
   PubMed Web of Science ®Google Scholar
• Bourquin C, Schmidt L, Lanz AL et al. Immunostimulatory RNA oligonucleotides induce an effective antitumoral NK cell response through the TLR7. J. Immunol. 183(10), 6078–6086(2009).
   PubMed Web of Science ®Google Scholar
• Chuang CM, Monie A, Hung CF, Wu TC. Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination. J. Biomed. Sci. 17, 32(2010).
   PubMed Web of Science ®Google Scholar
• Dumitru CD, Antonysamy MA, Gorski KS et al. NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model. Cancer Immunol. Immunother. 58(4), 575–587(2009).
   PubMed Web of Science ®Google Scholar
• Hamm S, Rath S, Michel S, Baumgartner R. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists. J. Immunotoxicol. 6(4), 257–265(2009).
   PubMed Web of Science ®Google Scholar
• Wysocka M, Newton S, Benoit BM et al. Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: synergy with interferon-gamma enhances production of interleukin-12. Clin. Lymphoma Myeloma 7(8), 524–534(2007).
   PubMedGoogle Scholar
• Grela F, Aumeunier A, Bardel E et al. The TLR7 agonist R848 alleviates allergic inflammation by targeting invariant NKT cells to produce IFN-gamma. J. Immunol. 186(1), 284–290(2011).
   PubMed Web of Science ®Google Scholar
• Dummer R, Hauschild A, Becker JC et al. An exploratory study of systemic administration of the Toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma. Clin. Cancer Res. 14(3), 856–864(2008).
   PubMed Web of Science ®Google Scholar
• Morse MA, Chapman R, Powderly J et al. Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients. Clin. Cancer Res. 17(14), 4844–4853(2011).
   PubMed Web of Science ®Google Scholar
• Huang SJ, Hijnen D, Murphy GF et al. Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin. J. Invest. Dermatol. 129(11), 2676–2685(2009).
   PubMed Web of Science ®Google Scholar
• Lu H, Wagner WM, Gad E et al. Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade. J. Immunol. 184(9), 5360–5367(2010).
   PubMed Web of Science ®Google Scholar
• Narayan R, Nguyen H, Bentow JJ et al. Immunomodulation by imiquimod in patients with high-risk primary melanoma. J. Invest. Dermatol. 132(1), 163–169(2012).
   PubMed Web of Science ®Google Scholar
• Xiong Z, Ohlfest JR. Topical imiquimod has therapeutic and immunomodulatory effects against intracranial tumors. J. Immunother. 34(3), 264–269(2011).
   PubMed Web of Science ®Google Scholar
• Bourquin C, Wurzenberger C, Heidegger S et al. Delivery of immunostimulatory RNA oligonucleotides by gelatin nanoparticles triggers an efficient antitumoral response. J. Immunother. 33(9), 935–944(2010).
   PubMed Web of Science ®Google Scholar
• Dang Y, Wagner WM, Gad E et al. Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells. Clin. Cancer Res. 18(11), 3122–3131(2012).
   PubMed Web of Science ®Google Scholar
• Bourquin C, Schmidt L, Hornung V et al. Immunostimulatory RNA oligonucleotides trigger an antigen-specific cytotoxic T-cell and IgG2a response. Blood 109(7), 2953–2960(2007).
   PubMed Web of Science ®Google Scholar
• Goldinger SM, Dummer R, Baumgaertner P et al. Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8(+) T-cell responses in melanoma patients. Eur. J. Immunol. 42(11), 3049–3061(2012).
   PubMed Web of Science ®Google Scholar
• Broomfield SA, Van Der Most RG, Prosser AC et al. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy. J. Immunol. 182(9), 5217–5224(2009).
   PubMed Web of Science ®Google Scholar
• Ma F, Zhang J, Zhang J, Zhang C. The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice. Cell. Mol. Immunol. 7(5), 381–388(2010).
   PubMed Web of Science ®Google Scholar
• Fiorenza S, Kenna TJ, Comerford I et al. A combination of local inflammation and central memory T cells potentiates immunotherapy in the skin. J. Immunol. 189(12), 5622–5631(2012).
   PubMed Web of Science ®Google Scholar
• Clark RA, Huang SJ, Murphy GF et al. Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. J. Exp. Med. 205(10), 2221–2234(2008).
   PubMed Web of Science ®Google Scholar
• Aranda F, Llopiz D, Diaz-Valdes N et al. Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors. Cancer Res. 71(9), 3214–3224(2011).
   PubMed Web of Science ®Google Scholar
• Warger T, Rechtsteiner G, Schmid B, Osterloh P, Schild H, Radsak MP. Transcutaneous immunization with imiquimod is amplified by CD40 ligation and results in sustained cytotoxic T-lymphocyte activation and tumor protection. Clin. Rev. Allerg. Immunol. 32(1), 57–66(2007).
   PubMed Web of Science ®Google Scholar
• Fotin-Mleczek M, Duchardt KM, Lorenz C et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J. Immunother. 34(1), 1–15(2011).
   PubMed Web of Science ®Google Scholar
• Adams S, O’Neill DW, Nonaka D et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J. Immunol. 181(1), 776–784(2008).
   PubMed Web of Science ®Google Scholar
• Bishop GA, Hsing Y, Hostager BS, Jalukar SV, Ramirez LM, Tomai MA. Molecular mechanisms of B lymphocyte activation by the immune response modifier R-848. J. Immunol. 165(10), 5552–5557(2000).
   PubMed Web of Science ®Google Scholar
• Tomai MA, Imbertson LM, Stanczak TL, Tygrett LT, Waldschmidt TJ. The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. Cell. Immunol. 203(1), 55–65(2000).
   PubMed Web of Science ®Google Scholar
• Green NM, Laws A, Kiefer K et al. Murine B cell response to TLR7 ligands depends on an IFN-beta feedback loop. J. Immunol. 183(3), 1569–1576(2009).
   PubMed Web of Science ®Google Scholar
• Shi Y, White D, He L, Miller RL, Spaner DE. Toll-like receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents. Cancer Res. 67(4), 1823–1831(2007).
   PubMed Web of Science ®Google Scholar
• Wolska A, Cebula-Obrzut B, Smolewski P, Robak T. Effects of Toll-like receptor 7 and Toll-like receptor 9 signaling stimulators and inhibitors on chronic lymphocytic leukemia cells ex vivo and their interactions with cladribine. Leuk. Lymph. 54(6), 1268–1278(2013).
   PubMed Web of Science ®Google Scholar
• Spaner DE, Shi Y, White D et al. Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells. Leukemia 20(2), 286–295(2006).
   PubMed Web of Science ®Google Scholar
• Wang D, Precopio M, Lan T et al. Antitumor activity and immune response induction of a dual agonist of Toll-like receptors 7 and 8. Mol. Cancer Ther. 9(6), 1788–1797(2010).
   PubMed Web of Science ®Google Scholar
• Shojaei H, Oberg HH, Juricke M et al. Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human gammadelta T cells. Cancer Res. 69(22), 8710–8717(2009).
   PubMed Web of Science ®Google Scholar
• Adlard AL, Dovedi SJ, Telfer BA et al. A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models. Int. J. Cancer 135(4), 820–829(2014).
   PubMed Web of Science ®Google Scholar
• Dewan MZ, Vanpouille-Box C, Kawashima N et al. Synergy of topical Toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer. Clin. Cancer Res. 18(24), 6668–6678(2012).
   PubMed Web of Science ®Google Scholar
• Dovedi SJ, Melis MH, Wilkinson RW et al. Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma. Blood 121(2), 251–259(2013).
   PubMed Web of Science ®Google Scholar
• Mangsbo SM, Sandin LC, Anger K, Korman AJ, Loskog A, Totterman TH. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.J. Immunother. 33(3), 225–235(2010).
   PubMed Web of Science ®Google Scholar
• Lanford RE, Guerra B, Chavez D et al. GS-9620, an oral agonist of Toll-like receptor-7, induces prolongedsuppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology(7), 1508–1517, 1517.e1–10(2013).
   PubMedGoogle Scholar